medical-affairs
(20)
The Hardest Part of a Breakthrough Is Explaining It
SIMPSON Healthcare built a business in the narrow gap between discovering a therapy and making its science understood. Inside IQVIA, that small Connecticut agency now has a much larger map.
The Company Selling Confidence Before a Medicine Can Be Sold
A drug can work perfectly and still fail to reach patients. OPEN Health built a global consultancy around the awkward middle - the evidence, access, education, and human judgment that turn a scientific result into a confident decision.
The Medicine Was Approved. Then the Hard Part Began.
Lucid Group built a business around an awkward truth in medicine: approval is only the beginning. Its job is to move evidence through the far messier machinery of belief, behaviour and clinical practice.
The Deck That Went Nowhere
A year of careful medical-communications work once died unused in the field. Kinetix Health Group is betting that pharma does not need another deck - it needs a system that keeps evidence moving.
The Medical Meeting That Refuses to End
Impact Communication Partners has spent more than four decades translating complicated science for healthcare professionals. Its sharpest idea is also its simplest: the best answer may arrive after the meeting is over.
The Drug Launch Has Too Many Translators
Citrus Health Group bought its way across the pharmaceutical launch journey. The clever part is not owning every specialty - it is deciding when each one enters the room.
Virgo Health Rickrolled Hearing Loss - Then Turned the Joke Into a Hearing Test
A London healthcare agency found its edge in a difficult combination: knowing the compliance rules cold, then making the work feel nothing like compliance. Its best proof is a Rick Astley joke that moved people to book hearing tests.
Synchrony Group and the Art of Making Medicine Make Sense
The West Chester agency built two businesses around one stubborn problem: good science is useless if nobody can understand, approve, or act on it.
The Agency Behind the Medicine Behind the Message
HCG built a business around an awkward truth: a medicine can work perfectly in a trial and still fail in the world if nobody understands it. Its answer was to put scientists, storytellers, designers, and regulatory specialists at the same table.
M Health Makes Healthcare Marketing by Hand
In an industry built for scale, this Philadelphia consultancy has made a business of resisting the assembly line - turning medical evidence, human behavior and stubborn constraints into communications people can actually use.
The Tiny Agency Behind the Footnotes
Kay Square Scientific turns clinical data into the papers, posters and expert conversations that medicine runs on. Its advantage is not size, but a small remote team with long memories, advanced degrees and an almost fussy respect for the footnote.
Twist Medical and the patient in the byline
A medical communications agency is helping patients enter the scientific conversation as contributors. Its publication credits show what that work looks like - and why listening is only the beginning.
Craig Hopkinson Turns Deep Science Into Medicines That Reach People
A doctor by training who now runs research, development and medical affairs at one of neuroscience's most watched biopharma companies - and keeps the patient at the center of every decision.
The AI that reads every medical paper so pharma's scientists don't have to
Medical teams at drug companies read maybe 10% of the evidence that matters. Sorcero built AI agents to read the other 90% - and about a third of the top 30 global pharma companies are now paying for it.
Gerald Denny Still Sees Patients Between Board Meetings
A practicing nephrologist who runs the medical side of a $1.9 billion device business, and still keeps a standing clinic day.
H1
H1 is a New York-based healthcare data and technology company that maps the world's healthcare professionals, clinical trials and provider networks into a single platform. Founded in 2017 by Ariel Katz and Ian Sax, H1 aggregates billions of data points - peer-reviewed publications, clinical trial records, medical claims and provider directories - so pharmaceutical, biotech, medtech, health-plan and digital-health customers can find the right doctors, run better clinical trials, engage key opinion leaders and keep provider information accurate. Its stated mission is to create a healthier future by making healthcare information and evidence-based medicine accessible globally.
Atrix AI
Atrix AI is a New York-based startup building a generative-AI platform for life sciences teams - medical affairs, commercial, clinical, and regulatory - to turn messy, siloed data and research into compliant, auditable insights. Its no-code workflow engine connects sources like MSL conversations, advisory-board outputs, and KOL engagement into dashboards, reports, and impact measurements without requiring engineers or data scientists. Founded by ex-Uber and ex-Meta engineer Vera Kutsenko, the company raised a seed round backed by Pear VC, Bling Capital, and others.
Synthio Labs
Synthio Labs builds clinical-grade voice and agentic AI for life sciences customer engagement. Its platform helps pharma field teams, medical affairs, and patient-support orgs run compliant, continuous conversations across HCPs and patients, powered by a clinical reasoning engine that ingests FDA labels and real-world evidence.
Vera Kutsenko
Vera Kutsenko is the founder and CEO of Atrix AI, a New York company building a trusted AI platform for life sciences that helps medical affairs teams at pharma and med-device companies turn messy real-world data into decisions they can act on. A Cornell-trained engineer who shipped code at Facebook and Uber, she is a two-time Y Combinator founder. Her previous startup, Neverland, was a venture-backed marketplace for houseplants and home gardening that raised $4.7M before closing. She is also a certified personal trainer who once ran her own plant nursery.
Eric Bolesh
Eric Bolesh is the Chief Executive Officer of Cutting Edge Information, a Research Triangle Park firm that has become the de facto industry standard for fair market value (FMV) data in life sciences. One of the company's first employees back in 2002, he spent two decades turning the murky question of what a cardiologist in Bulgaria or a pharmacist in the UK should be paid into a defensible, data-driven discipline. A Harvard graduate and frequent speaker at compliance conferences, he is widely regarded as a thought leader on healthcare-provider engagement and the economics of compliant compensation across more than 130 global markets.